Monopar Therapeutics (MNPR) Competitors $32.33 +0.49 (+1.54%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. PGEN, AKBA, AVXL, NRIX, NAGE, PHAR, AVBP, SANA, GYRE, and OCSShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Precigen (PGEN), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Precigen Akebia Therapeutics Anavex Life Sciences Nurix Therapeutics Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Monopar Therapeutics (NASDAQ:MNPR) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Do insiders and institutionals believe in MNPR or PGEN? 1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, MNPR or PGEN? Monopar Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Is MNPR or PGEN more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -2,868.66%. Monopar Therapeutics' return on equity of -41.76% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -41.76% -39.49% Precigen -2,868.66%-842.83%-78.98% Does the media refer more to MNPR or PGEN? In the previous week, Precigen had 34 more articles in the media than Monopar Therapeutics. MarketBeat recorded 47 mentions for Precigen and 13 mentions for Monopar Therapeutics. Precigen's average media sentiment score of 0.52 beat Monopar Therapeutics' score of 0.45 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 15 Very Positive mention(s) 9 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, MNPR or PGEN? Monopar Therapeutics has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.33-9.71Precigen$3.92M316.59-$126.24M-$0.42-9.92 Do analysts recommend MNPR or PGEN? Monopar Therapeutics presently has a consensus price target of $60.00, indicating a potential upside of 85.59%. Precigen has a consensus price target of $8.25, indicating a potential upside of 98.08%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Precigen 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryPrecigen beats Monopar Therapeutics on 8 of the 15 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.61M$3.09B$5.82B$9.75BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-9.6721.0131.1425.96Price / SalesN/A396.98475.48122.90Price / CashN/A43.0937.1558.38Price / Book3.828.069.116.38Net Income-$15.59M-$54.72M$3.26B$265.56M7 Day Performance-9.47%2.30%1.94%1.81%1 Month Performance-28.51%7.21%4.91%1.14%1 Year Performance1,071.34%12.85%31.21%20.98% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics2.9046 of 5 stars$32.33+1.5%$60.00+85.6%+1,134.1%$198.61MN/A-9.6710PGENPrecigen3.9134 of 5 stars$2.95+0.3%$6.00+103.4%+205.9%$876.04M$3.92M-7.02190News CoverageAnalyst ForecastOptions VolumeAnalyst RevisionAKBAAkebia Therapeutics3.8876 of 5 stars$3.11-4.3%$6.75+117.0%+114.1%$861.72M$203.73M-18.29430AVXLAnavex Life Sciences3.9212 of 5 stars$9.59-3.5%$44.00+358.8%+50.4%$854.21MN/A-16.8240Analyst ForecastNRIXNurix Therapeutics2.3985 of 5 stars$10.20-3.6%$28.87+183.0%-59.6%$808.83M$54.55M-3.91300High Trading VolumeNAGENiagen Bioscience1.3419 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.13M$116.30M48.19120PHARPharming Group2.0036 of 5 stars$12.39+6.4%$30.00+142.1%+54.8%$798.20M$297.20M-95.31280Gap UpAVBPArriVent BioPharma2.4707 of 5 stars$19.24-1.5%$39.14+103.4%-16.9%$792.31MN/A-4.7940SANASana Biotechnology2.9986 of 5 stars$3.40+2.1%$8.00+135.3%-32.1%$791.90MN/A-3.21380GYREGyre Therapeutics0.1195 of 5 stars$7.85-3.6%N/A-36.9%$783.99M$102.19M785.7940Gap UpOCSOculis3.2654 of 5 stars$18.06+0.9%$35.33+95.6%+49.1%$781.56M$780K-6.842News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Precigen Alternatives Akebia Therapeutics Alternatives Anavex Life Sciences Alternatives Nurix Therapeutics Alternatives Niagen Bioscience Alternatives Pharming Group Alternatives ArriVent BioPharma Alternatives Sana Biotechnology Alternatives Gyre Therapeutics Alternatives Oculis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.